Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TelyRx HoldingsTSX:TELY +13.04%12 EV-to-EBIT is -9.52 as of Jul. 31, 2026. GuruFocus rates TSX:TELY with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 471 Healthcare Providers & Services companies, TelyRx Holdings ranks worse than 212314.01% on this metric.
The historical rank and industry rank for TelyRx Holdings's EV-to-EBIT or its related term are showing as below:
TSX:TELY'
s EV-to-EBIT Range Over the Past 10 Years
Min: -10.73 Med: -4.4 Max: -3.13
Current: -9.5
During the past 3 years, the highest EV-to-EBIT of TelyRx Holdings was -3.13. The lowest was -10.73. And the median was -4.40.
TSX:TELY's EV-to-EBIT is ranked worse than 100% of 471
companies
in the Healthcare Providers & Services industry
Industry Median: 15.84
vs TSX:TELY: -9.50
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
TelyRx Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was C$0.00 Mil.
TelyRx Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-11.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TelyRx Holdings EV-to-EBIT Related Terms
TelyRx Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for TelyRx Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, TelyRx Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TelyRx Holdings EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, TelyRx Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where TelyRx Holdings's EV-to-EBIT falls into.
TelyRx Holdings's current Enterprise Value is C$106.98 Mil.
TelyRx Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-11.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TelyRx Holdings (TSX:TELY) has a EV-to-EBIT of -9.52 as of Jul. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on TelyRx Holdings and its competitors. According to the industry distribution chart, TelyRx Holdings ranks #999999 out of 471 companies in the Healthcare Providers & Services industry.
Is TelyRx Holdings' EV-to-EBIT too high?
TelyRx Holdings' current EV-to-EBIT is -9.52. Based on the distribution chart, TelyRx Holdings ranks #999999 out of 471 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, TelyRx Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does TelyRx Holdings' EV-to-EBIT compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, TelyRx Holdings ranks #999999 out of 471 companies for EV-to-EBIT. This places TelyRx Holdings in the lower half of its industry. The industry median EV-to-EBIT is 15.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.84, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on TelyRx Holdings and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TelyRx Holdings's current EV-to-EBIT is -9.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TelyRx Holdings stock overvalued right now?
TelyRx Holdings (TSX:TELY) has a current EV-to-EBIT of -9.52. The current EV-to-EBIT is -9.52. TelyRx Holdings' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For TelyRx Holdings (TSX:TELY), the current EV-to-EBIT is -9.52 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TelyRx Holdings Inc is a vertically integrated technology enabled healthcare and pharmacy services provider, operating a digital pharmacy platform that connects patients with independent, state-licensed providers. The TelyRx platform provides the Providers with access to a clinically focused electronic medical records system and the ability for them to electronically prescribe. TelyRx enables patient access to a risk-curated formulary of over 450 noncontrolled, and non-compounded prescription medications selected by the Providers to address a broad cross-section of everyday chronic and acute ailments.
12GF Score
Get the complete analysis for TSX:TELY
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:TELY has been successfully added to your 
